Merus discovers and develops innovative therapeutic human antibodies with improved clinical efficacy based on its single light chain (sLC) antibody technologies
Single light chain (sLC) antibodies are built from diverse immunoglobulin heavy chains but share a common light chain while retaining the exquisite specificity and high affinity of antibodies with diversified light chains. Multiple sLC human antibodies against different epitopes/targets are efficiently co-expressed in a single manufacturing cell to generate novel antibody formats like full length IgG Biclonics™ and mixtures of IgG antibodies (Oligoclonics™). By combining multiple mechanisms of action, these formats provide the basis for enhanced disease-modifying targeted therapies.
Based on these technologies Merus is building a pipeline of innovative therapeutic antibodies with improved clinical efficacy in multiple therapeutic areas.
